Table 4 Outcomes under alternative assumptions for the TF3+ population
Alternative assumption | Migraines averted versus BSC | Cost of eptinezumab | Incremental discounted total costs | Incremental discounted QALYs | Net monetary benefit |
|---|---|---|---|---|---|
Base case | 146 | £7,497 | –£4,894 | 0.231 | £9,515 |
Period of BSC benefit doubled to two years | 143 | £7,497 | –£4,850 | 0.228 | £9,411 |
BSC excluded as a further treatment after a regimen of eptinezumab | 141 | £7,497 | –£4,572 | 0.226 | £9,100 |
Exclusion of treatment holidays | 156 | £9,318 | –£3,215 | 0.255 | £8,323 |
Exclusion of natural history and treatment holidays | 169 | £9,717 | –£3,207 | 0.271 | £8,634 |
Response threshold in chronic migraine raised from 30 to 50% improvement | 113 | £5,528 | –£6,159 | 0.181 | £9,782 |
Discontinuation from other causes allowed beyond two years | 148 | £7,431 | –£5,059 | 0.235 | £9,759 |
Disutility included for possible fear/pain/anxiety associated with intravenous administration | 146 | £7,497 | –£4,894 | 0.204 | £8,969 |
Cost of one day of presenteeism reduced from a full day to half a day | 146 | £7,497 | –£415 | 0.231 | £5,036 |
One fully impaired day of work productivity for each occasion of eptinezumab administration | 146 | £7,497 | –£4,627 | 0.231 | £9,247 |
Payer perspective only, exclusion of work productivity benefit | 146 | £7,497 | £7,655 | 0.231 | –£3,035 (ICER = £33,138) |